| 06/22 | Biogen Inc. - European Patent Office Grants Patent Related to TECFIDERA (Dimethyl Fumar.. | AQ |
| 06/22 | Biogen and Happify Health Collaborate to Support Multiple Sclerosis Patients on Digital.. | BU |
| 06/21 | BIOGEN INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote o.. | AQ |
| 06/21 | European Patent Office Grants Patent Related to TECFIDERA® (Dimethyl Fumarate) | GL |
| 06/16 | Biogen Inc. - New Data Presented at Cure SMA Reveal Residual Unmet Needs in Young SMA P.. | AQ |
| 06/15 | BIOGEN : Annual Stockholder Presentation 2022 | PU |
| 06/15 | BIOGEN : Appreciation Statement for Retiring Board Members Nancy Leaming and Brian Posner | PU |
| 06/15 | New Data Presented at Cure SMA Reveal Residual Unmet Needs in Young SMA Patients Treate.. | GL |
| 06/15 | New Data Presented at Cure SMA Reveal Residual Unmet Needs in Young SMA Patients Treate.. | AQ |
| 06/14 | The Biogen Foundation and Community Lab Celebrates 20 Years of Serving our Communities | GL |
| 06/08 | Biogen And Samsung Bioepis Launch BYOOVIZ (ranibizumab-nuna) | AQ |
| 06/08 | BIOGEN : Withdrawal from the Jefferies Healthcare Conference | PU |
| 06/06 | Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar.. | AQ |
| 06/06 | Biogen Inc. - New 12-Month Tofersen Data Presented at ENCALS Meeting Show Clinically Me.. | AQ |
| 06/06 | Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL0181.. | GL |
| 06/06 | Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL0181.. | AQ |
| 06/03 | Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar.. | GL |
| 06/03 | Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar.. | AQ |
| 06/03 | New 12-Month Tofersen Data Presented at ENCALS Meeting Show Clinically Meaningful Benef.. | GL |
| 06/03 | New 12-Month Tofersen Data Presented at ENCALS Meeting Show Clinically Meaningful Benef.. | AQ |
| 06/02 | Biogen and Samsung Bioepis' BYOOVIZ™ (ranibizumab-nuna) Launches in the United St.. | AQ |
| 05/31 | Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor.. | AQ |
| 05/27 | BIOGEN : to Participate in the Jefferies Healthcare Conference | PU |
| 05/05 | Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic T.. | BU |
| 05/05 | Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic T.. | GL |
| 05/05 | Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic T.. | AQ |
| 05/05 | Xbrane Biopharma releases interim report for January – March 2022 | AQ |
| 05/03 | BIOGEN INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF.. | AQ |
| 05/03 | Change at the top for Biogen after Alzheimer's drug flops | AQ |
| 05/03 | BIOGEN INC. : Results of Operations and Financial Condition, Change in Directors or Princi.. | AQ |
| 05/03 | BIOGEN : Reports First Quarter 2022 Results | PU |
| 05/03 | BIOGEN : Q1 2021 Biogen Earnings Presentation | PU |
| 04/29 | BIOGEN : Statement Regarding Updated ADUHELM® (aducanumab-avwa) Prescribing Information in.. | PU |
| 04/28 | Samsung Biologics Completes Full Acquisition Of Samsung Bioepis | AQ |
| 04/22 | BIOGEN : Update on Regulatory Submission for Aducanumab in the European Union | PU |
| 04/20 | BIOGEN : Completes Sale of Equity Stake in Biosimilar Joint Venture to Samsung Biologics f.. | PU |
| 04/07 | BIOGEN : Statement on the Final National Coverage Determination for Amyloid-Beta Targeting.. | PU |
| 04/05 | BIOGEN : to Report First Quarter 2022 Financial Results May 3, 2022 | PU |
| 04/04 | New Data at AAN 2022 Highlight Real-World Evidence from Biogen's MS Portfolio and Emerg.. | AQ |
| 03/30 | Biogen Submits Final Protocol for ADUHELM® (aducanumab-avwa) Phase 4 ENVISION Trial to .. | AQ |
| 03/28 | Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9or.. | AQ |
| 03/23 | Eisai Co., Ltd - LATEST FINDINGS ON LECANEMAB - CLINICAL EFFICACY, ARIA RATES, BIOMARKE.. | AQ |
| 03/22 | Latest Findings on Lecanemab - Clinical Efficacy, Aria Rates, Biomarkers Relationship t.. | AQ |
| 03/18 | BIOGEN : The National Minority Quality Forum and Biogen Highlight Equitable Access to Rese.. | PU |
| 03/17 | BIOGEN : to Participate in the Stifel 2022 CNS Days | PU |
| 03/17 | Biogen Announces Peer-Reviewed Publication of ADUHELM Phase 3 EMERGE and ENGAGE Data in.. | AQ |
| 03/17 | Long-Term Phase 3 Data Show ADUHELM Continues to Reduce Underlying Pathologies of Alzhe.. | AQ |
| 03/16 | Biogen Announces Peer-Reviewed Publication of ADUHELM® Phase 3 EMERGE and ENGAGE Data i.. | GL |
| 03/16 | Biogen Announces Peer-Reviewed Publication of ADUHELM® Phase 3 EMERGE and ENGAGE Data i.. | GL |
| 03/16 | Long-Term Phase 3 Data Show ADUHELM® Continues to Reduce Underlying Pathologies of Alzh.. | AQ |
| 03/15 | Eisai - ECONOMIC ARRANGEMENTS OF AMENDMENT TO ALZHEIMER'S DISEASE TREATMENT COLLABORATI.. | AQ |
| 03/14 | Biogen and Eisai amend collaboration agreements on Alzheimer's disease treatments | AQ |
| 03/14 | Biogen to Present New Research at the International Conference on Alzheimer's and Parki.. | AQ |
| 03/14 | Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference | AQ |
| 03/11 | Biogen to Present New Research at the International Conference on Alzheimer's and Parki.. | AQ |
| 03/07 | Eisai initiates submission of application data under the prior assessment consultation .. | AQ |
| 03/03 | BIOGEN INC. COMPANY NEWS : Berger Montague Investigates Securities Fraud Allegations Again.. | PR |
| 03/03 | Eisai initiates submission of application data under the prior assessment consultation .. | PR |
| 02/24 | Xbrane Biopharma releases Year-end report 2021 | AQ |
| 02/18 | BIOGEN : to Present at the Cowen 42nd Annual Health Care Conference | PU |
| 02/17 | Sage Therapeutics and Biogen Announce the Phase 3 CORAL Study Met its Primary and Key S.. | AQ |
| 02/17 | Biogen And Xbrane Enter Into Worldwide Commercialization And License Agreement For Cert.. | AQ |
| 02/11 | Biogen Submits Response to the Centers for Medicare and Medicaid Services (CMS) Propose.. | AQ |
| 02/10 | BIOGEN : Submits Response to the Centers for Medicare and Medicaid Services (CMS) Proposed.. | PU |
| 02/08 | Biogen and xbrane announce commercialization and license agreement for proposed biosimi.. | AQ |
| 02/07 | Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimi.. | AQ |
| 02/04 | Biogen reports fourth quarter and full year 2021 results | AQ |
| 02/03 | BIOGEN INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF.. | AQ |
| 02/03 | Biogen's 2022 outlook leaves investors wanting, shares slip | AQ |
| 02/03 | BIOGEN : Q4 2021 Biogen Earnings Presentation | PU |
| 02/03 | BIOGEN : REPORTS FOURTH QUARTER AND FULL YEAR 2021 RESULTS - Form 8-K | PU |
| 02/03 | BIOGEN : Reports Q4 2021 Earnings | PU |
| 02/01 | Biogen Exercises Option to Participate in the Development and Commercialization of a La.. | AQ |
| 01/31 | BIOGEN : Announces Nancy Leaming and Brian Posner to Retire from Board of Directors - Form.. | PU |
| 01/31 | BIOGEN INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits.. | AQ |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
